By Julie Steenhuysen CHICAGO, June 9 (Reuters) - Treatments based on the same mRNA technology that delivered COVID-19 ...

A personalized mRNA cancer vaccine developed by Moderna and Merck — when combined with the immunotherapy drug Keytruda — ...

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...

The battle against the most dangerous type of skin cancer has made a huge leap forward, and it could dramatically change the ...

Researchers are particularly encouraged by new data involving a personalized mRNA therapy developed by Moderna and Merck.

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the ...

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance ...

We are celebrating that breakthrough at the precise moment Washington is taking apart the research base behind it.

A new treatment platform developed by researchers at the University of Texas MD Anderson Cancer Center was able to deliver ...